Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab, a late-stage asset ...
Genmab to acquire clinical-stage biotechnology company, Merus for USD 8 billion: Copenhagen, Denmark Tuesday, September 30, 2025, 09:00 Hrs [IST] Genmab A/S and Merus N.V. announc ...
The DNA synthesis inhibitors market is projected to witness substantial growth in the coming years, driven by the rising incidence of cancer diagnoses, growing awareness, the expanding pipeline ...
Enhertu plus pertuzumab granted Priority Review in US as 1st-line treatment for patients with HER2-positive metastatic breast cancer: Cambridge, UK Thursday, September 25, 2025, 0 ...
The Steam Autumn Sale 2025 is now live and with it you can get lots of games heavily discounted, one of the best times to stock up.
Final Issues Have Been Clarified Identifying Basic Safety Concerns Del Mar, California–(Newsfile Corp. –) – American Diversified Holdings Corporation (OTCID: ADHC) today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback